New Delhi: India’s drug regulator has suspended Entod Pharmaceutical Ltd.’s authorization to manufacture and market a specific eye drop product, citing the company’s unapproved promotional claims. The Drugs Controller General of India…
Category: World
Short-acting insulin market to cross $9b by 2030
The global short-acting insulin market is anticipated to exceed $9 billion by 2030, largely fueled by the increasing prevalence of diabetes, according to DelveInsight. Key factors driving this growth include significant technological…
Boston Institute of Biotechnology & BiBo Pharma CEO Wins 2024 Global Biologics CDMO Technology Leadership Award
The Boston Institute of Biotechnology, LLC (BIB) is proud to announce that its CEO has been awarded the prestigious 2024 Global Biologics CDMO Technology Leadership Award from Frost & Sullivan. This recognition…
After BIOSECURE Act passes in House, targeted Chinese companies say they’re ‘deeply’ concerned
After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. Late Monday, the U.S. House of Representatives voted…
FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections
Two Japanese drugmakers and another in India were hit with Form 483s from the FDA following inspections that uncovered issues ranging from a lack of sanitary procedures to improper data collection and…
BIOSECURE Act heads for possible vote in House of Representatives next week
After running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week. The U.S. House of Representatives is slated to consider the legislation during the…
GSK posts COPD win for Nucala as Sanofi-Regeneron rival Dupixent nears delayed FDA decision
GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On Friday, GSK said that its IL-5 antibody Nucala plus inhaled maintenance…